Drug Profile

EG 009A

Alternative Names: EG-009A

Latest Information Update: 11 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evergreen Therapeutics
Class Anti-inflammatories; Antivirals
Mechanism of Action Cytokine inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Cytokine release syndrome

Most Recent Events

11 Apr 2022 Phase-II clinical trials in Cytokine release syndrome in China (Injection) (Evergreen Therapeutic pipeline, April 2022)
18 Jun 2021 Evergreen Therapeutics plans a phase II trial for COVID-2019 infections in USA, Brazil, and Argentina. The company plans to start the enrolment in early August 2021
18 Jun 2021 Evergreen Therapeutics enters into a clinical service agreement with ICON to conduct a phase II trial in COVID-2019 infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com